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incidence (assuming 1 occurrence/patient/cycle), treatment usage, and 1-year 
prevalence of MM (2124 cases) to estimate the treatment burden in Australia for a 
single AE occurrence. Results: The most cost-intensive AEs were all Gr 3/4. For TT, 
the most cost-intensive AEs were squamous cell carcinoma (SCC) and rash, with 
a mean cost per event per patient of A$228 and A$223, respectively. For IT, they 
were colitis and diarrhea, with a mean cost of A$1471 and A$1333, respectively. 
For CT, they were neutropenia/leukopenia and anaphylaxis, representing a mean 
cost of A$1005 and A$381, respectively. Across all 3 treatment categories, the top 
4 AEs with the highest burden were all Gr 3/4 and included neutropenia/leukope-
nia (mean total cost of A$92,453), colitis (A$72,346), diarrhea (A$69,399), and SCC 
(A$30,636). ConClusions: In Australia, costs for management of AEs associated 
with MM therapies can be substantial. Since we did not account for multiple AE 
occurrences, the total burden is likely to be an underestimate.
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objeCtives: To understand the proportion of total medical costs attributed to can-
cer drug treatment in oncology patients, with a focus on breast and prostate can-
cer. Methods: Literature review conducted using PubMed, Medscape and Google 
to identify and retrieve studies in cancer patients reporting total medical costs and 
cost components, particularly cancer drug treatment costs. All studies reporting 
data on US American patients published in English language between 2009 and 2013 
were included. Results: A total of 5565 studies were reviewed, 14 of which were 
relevant and included. Total medical costs and cost components varied substantially 
by tumor type and location, cancer stage, phase of care, study design, payers and 
the way drug and treatment costs were defined and reported. In 2011, oncology 
care costs accounted for $125 billion. Prescription drug costs were 1.8–13.9% of total 
cancer care costs, with 13.9% representing the proportion of costs during the last six 
months of life. Studies of breast cancer patients reported that drugs accounted for 
2.4–37.0% of total costs, with the lowest proportion occurring in newly diagnosed 
and the highest in metastatic patients, respectively. Outpatient visits were the pri-
mary cost driver, accounting for 64.0-82.0% of total costs. Among patients receiving 
chemotherapy as their primary treatment, chemotherapy costs accounted for 25.0% 
and other medications (e.g., analgesics, sedatives, anti-emetics, antidepressants) 
accounted for 26.0% of total costs. None of the prostate cancer studies identified met 
the research inclusion criteria. ConClusions: Studies on drug treatment costs are 
limited and results vary substantially depending on patient clinical characteristics, 
cancer stage, and disease progression. Existing studies suggest that although medi-
cal costs are high overall, cancer drug treatment costs only contribute 1.8–13.9% of 
total cancer costs, and 2.4–37.0% in breast cancer.
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objeCtives: Manufacturer listed prices do not represent real transactions prices 
but are often used to set up reimbursement rates for third-party payers. This study 
evaluates approvals, discontinuations, and price trends of oncology drugs approved 
by the US Food and Drug Administration (FDA) in the period 1990-2013. Methods: 
Drug regulatory information derived from the FDA. Average wholesaler prices (AWP) 
per unit were collected from the RedBook. Annual average price changes were cal-
culated for each drug as the increase in prices from market entry to Dec-31-2013 
divided by the number of years between the effective dates of those prices. Prices 
were converted to 2013 year dollars using the consumer price index (CPI). Descriptive 
statistics and 95% confidence intervals and t-tests were performed in the analy-
sis. Results: The FDA listed 165 approved oncology therapeutic drugs (44 biologics 
and 121 chemical entities) in the period of analysis. The FDA approved 31 products 
(18% of total) before the 1980s, 11 (6.7%) in the 1980s, 50 (30.3%) in the 1990s, 48 
(29.1%) in the 2000s, and 25 (15.2%) in 2010-2103. There were 45 (27.3%) products 
with at least one FDA approved orphan indication. There were 10 products (6.1% 
of approvals) discontinued. There were 45 products with complete price history 
from approval to January 1,2014, and 2 had generic competition. The CPI adjusted 
average annual AWP price increase was 10.2%±21.0% (95%CI:8.2%-12.1%); with an 
average 9.18±6.59 years in the market. The average annual AWP increase was higher 
for products approved in the 1990s (20.9%±34.8%) than for those approved in the 
2000’s (5.0%±5.2%) and 2000-2013 (6.3%±9.8%). Chemical entities and drugs with 
orphan indications had higher AWP price increases than biologics and non-orphan 
drugs, respectively. ConClusions: Manufacturer listed prices of oncology products 
approved in the period 1990-2013 grew faster than the inflation. Price increases were 
higher for orphan drugs and chemical entities.
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objeCtives: Since approval of imatinib, systemic therapy (ST) for gastrointestinal 
stromal tumors (GIST) has changed considerably. This study evaluated treatment pat-
terns and costs across 3 large retrospective databases among GIST patients receiv-
(IRR= 2.68); BV had higher proteinuria (IRR= 0.64; p< 0.01). GI perforation incidence 
rates trended higher (p> 0.05) with BV (LOT1:0.02 vs. 0; LOT2:0.001 vs. 0). BV patients 
had lower per-patient per-month (PPPM) total costs (LOT1 adj. difference: –$4,202, 
p< 0.01; LOT2: -$3,776, p= 0.01), and PPPM AE medical costs (LOT1:-$5,851, p< 0.01; 
LOT2: –$4,293, p= 0.02). ConClusions: BV during first or second line mCRC treat-
ment was associated with lower AE rates and lower PPPM costs compared to CET. 
Limitations include the inability to distinguish events related to targeted vs. chemo 
agents and high baseline rates of certain events (e.g., hypertension).
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objeCtives: Early stage breast cancer is treated with surgery plus adjuvant ther-
apy which may include radiation, cytotoxic chemotherapy, and hormonal therapy 
resulting in substantial cost variation. Understanding costs is essential to estab-
lishing aberrant billing and clinical practice variation. Methods: This naturalistic 
study assessed 10 million commercial members younger than 65. Claims data from 
January 2009 through December 2012 was assessed. During 2010-2011, members 
with primary breast cancer surgery, defined as the first diagnosis coded breast can-
cer claim lumpectomy or mastectomy claim and continuous enrollment > = 365 days 
before and after surgery were identified and categorized into three groups: receiving 
no chemotherapy, cytotoxic chemotherapy without trastuzumab, or chemotherapy 
including trastuzumab. Members were excluded if there was claims evidence for 
metastatic breast cancer or any radiation therapy before surgery. The start date was 
the first cytotoxic chemotherapy claim, if it occurred prior to surgery, otherwise it 
was the surgery date. Medical and pharmacy claims expenses were summed for 
the post 365-day interval beginning at the earlier of the surgery date or start of 
neoadjuvant chemotherapy. Results: 5,050 members met analysis criteria; 2,437 
(48.3%) no chemotherapy, 1,965 (38.9%) chemotherapy without trastuzumab, and 648 
(12.8%) chemotherapy plus trastuzumab, and average medical plus pharmacy claims 
expense for members in these categories for the 365-day interval was $49,392, 
$99,646, and $169,083, respectively. Average chemotherapy costs for members receiv-
ing chemotherapy without trastuzumab (n= 1,965) was $11,695 and for members 
with trastuzumab (n= 648) $74,048. ConClusions: The cost of early stage breast 
cancer therapy varies by the three described treatment categories. Compared with 
the no chemotherapy group, average expenses for all medical and pharmacy claims 
in a 365-day interval was $50,254 higher for members who received chemotherapy 
without trastuzumab, and $119,691 higher for the group with chemotherapy includ-
ing trastuzumab. Member cost distributions between and within these categories 
will be helpful in developing managed care strategies.
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objeCtives: Chemotherapy (CT), targeted therapy (TT), and immunotherapy (IT), 
which are commonly used to treat MM, are often associated with adverse effects 
(AEs). This study estimated the per-event cost and economic burden associated 
with managing the most common and/or severe AEs for these 3 treatment cat-
egories from the UK National Health Service perspective. Methods: A literature 
review evaluated the incidence and types of AEs associated with the 3 treatment 
categories. A total of 29 AEs (CT:11; TT:11; and IT:7), all-severity grades (Gr) occurring 
in > 20% or Gr 3/4 occurring in > 5%, were selected. Medical resource use related to 
the management of AEs was assessed by conducting 2 blinded Delphi panel cycles 
with 4 clinicians. Published unit costs were used to estimate the costs per AE and 
then combined with AE incidence (assuming 1 occurrence/patient/cycle), treatment 
usage, and 1-year prevalence of MM (2027 cases) to estimate treatment burden in the 
UK for a single AE occurrence. Results: For CT, the most cost-intensive AEs were 
Gr 3/4 peripheral neuropathy and thrombocytopenia, representing a mean cost per 
event per patient of £432 and £277, respectively. For TT, they were Gr 3/4 squamous 
cell carcinoma (SCC) and Gr 1/2 skin papilloma, with a mean cost of £1281 and £845, 
respectively. For IT, they were Gr 3/4 diarrhea and colitis, both with a mean cost 
of £2836. The top 5 AEs with the highest treatment burden across all 3 categories 
included Gr 3/4 SCC (mean total cost of £202,493), Gr 3/4 diarrhea (£132,032), Gr 
1/2 skin papilloma (£125,995), Gr 3/4 colitis (£124,695) and Gr 3/4 immune-related 
hypophysitis (£98,393), and Gr 1/2 hyperkeratosis (£70,292). ConClusions: In the 
UK, costs for management of AEs associated with MM therapies can be substantial. 
The total burden may be underestimated since it does not account for AE recurrence.
PCN78
Cost burdeN of adverse effeCts assoCiated with MetastatiC 
MeLaNoMa (MM) theraPies iN austraLia
Benter U.1, Amonkar M.2, Vouk K.1
1INC Research GmbH, Munich, Germany, 2GlaxoSmithKline, Collegeville, PA, USA
objeCtives: Targeted therapy (TT), immunotherapy (IT), and chemotherapy (CT), 
which are commonly used in the treatment of MM, are frequently associated with 
adverse effects (AEs). This study estimated the per-event cost and economic burden 
associated with managing the most common and/or severe AEs for these 3 treat-
ment categories from the Australian statutory health insurance system perspec-
tive. Methods: The study involved a literature review to evaluate the incidence 
and types of AEs associated with the 3 treatment categories. A total of 29 AEs (CT:11; 
TT:11; and IT:7), all-severity grades (Gr) occurring in > 20% or Gr 3/4 occurring in 
> 5%, were selected. Medical resource use related to the management of AEs was 
assessed by conducting 2 blinded Delphi panel cycles with 5 clinicians. Published 
unit costs were used to estimate the costs per AE and then combined with AE 
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objeCtives: Clinicians treating patients with advanced NSCLC have a range of 
options for care. The objective of this study was to develop a cost-effectiveness 
(CE) model to compare induction-maintenance sequences approved for use in the 
U.S. for the treatment of advanced non-squamous NSCLC given the absence of 
direct head-to-head trials. Methods: The modelled regimens that were licensed 
in the United States included pemetrexed+cisplatin followed by (→ ) pemetrexed; 
pemetrexed+cisplatin→ best supportive care (BSC); gemcitabine+cisplatin→ BSC; 
gemcitabine+cisplatin→ erlotinib; gemcitabine+cisplatin→ pemetrexed; and pac
litaxel+carboplatin+bevacizumab→ bevacizumab. Treatment effects of induction 
and maintenance on survival endpoints were obtained using data from a previ-
ous network meta-analysis. Decision analytic modelling was used to synthesise 
the treatment effect and baseline risk estimates for the induction and mainte-
nance treatment sequences. The CE model was structured using an area-under-
the-curve approach, costs and benefits were discounted at 3.5% per annum, 
and probabilistic and one-way sensitivity analyses were conducted to evaluate 
model parameters. Results: All active maintenance therapy-containing regi-
mens, with the exception of gemcitabine+cisplatin→ erlotinib, were more costly 
than induction-only regimens. Gemcitabine+cisplatin→ BSC was the baseline 
comparator and established the cost effective threshold range of $0 to $121,425. 
The respective incremental costs per life year (LY) were $121,425, $148,994, and 
$191,270 for gemcitabine+cisplatin→ erlotinib versus gemcitabine+cisplatin→ BSC, 
pemetrexed+cisplatin→ BSC versus gemcitabine+cisplatin→ erlotinib, and 
pemetrexed+cisplatin→ pemetrexed versus pemetrexed+cisplatin→ BSC. 
Other regimens were dominated (paclitaxel+carboplatin+bevacizumab→ beva-
cizumab) or extendedly dominated (gemcitabine+cisplatin→ pemetrexed). 
Sensitivity analyses demonstrated that efficacy data and the method of extrap-
olating survival had the greatest impact on the cost-effectiveness results. 
For non-dominated regimens, the cost-effectiveness acceptability frontier 
showed that gemcitabine+cisplatin→ BSC, pemetrexed+cisplatin→ BSC, and 
pemetrexed+cisplatin→ pemetrexed had the greatest probabilities of cost-effec-
tiveness over the following threshold ranges: $0-$124,000/LY; $124,000-$220,000/
LY; and above $220,000/LY, respectively. ConClusions: Depending on the specific 
cost-effectiveness threshold used by a decision maker, the cost-effective treatment 
sequence will be gemcitabine+cisplatin→ BSC, gemcitabine+cisplatin→ erlotinib, 
pemetrexed+cisplatin→ BSC, or pemetrexed+cisplatin→ pemetrexed. Paclitaxel+c
arboplatin+bevacizumab→ bevacizumab and gemcitabine+cisplatin→ pemetrexed 
were dominated or extendedly dominated and thus not cost-effective when rank-
ing these comparators.
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objeCtives: As antiretroviral therapy is scaled up in Africa, HIV-positive women 
are increasingly likely to die from cervical cancer, a leading cause of cancer death. 
Effective screens for cervical cancer exist including Papanicolaou smear (Pap), 
visual inspection of the cervix with acetic acid (VIA), and human papillomavirus 
testing (HPV). Our objective was to prospectively assess cost-effectiveness of cervi-
cal cancer screening methods for HIV-positive women. Methods: The analysis 
was based on data from 500 HIV-positive women who underwent VIA, Pap, HPV, 
and gold-standard colposcopy-directed biopsy in Nairobi, Kenya. A Markov model 
projected life expectancy and costs for six cervical screening strategies: Pap; VIA; 
HPV; testing positive for both VIA+Pap, Pap+HPV, VIA+HPV. Cost-effectiveness was 
calculated for overall population and by CD4 count. Strategies were compared 
using an incremental cost-effectiveness ratio (ICER)—the additional cost per life 
year (LY) gained. Impact of parameter uncertainty was addressed using univariate 
and probabilistic multivariate sensitivity analysis. Results: VIA had lowest cost 
and highest life expectancy ($331, 17.2 LYs), followed by HPV ($569, 17.1 LYs), Pap 
($622, 17.1 LYs), HPV+Pap ($836, 17.0 LYs), VIA+HPV ($857, 17.0 LYs), and VIA+Pap 
($897, 17.0 LYs). CD4 level did not affect this rank order, though VIA at low CD4 
showed the lowest cost ($111, 15.3 LY), while VIA at high CD4 produced most health 
gains ($285, 19.9 LY) [ICER: $37/LY]. Costs were sensitive to prevalence of cancer, 
sensitivity, age, and cost of cancer. Life expectancy was sensitive to age at screen-
ing. Results were robust to probabilistic sensitivity analysis. ConClusions: VIA 
is projected to be the most cost-effective screening strategy for cervical cancer 
among HIV-positive women. This is due to its high sensitivity, low screening cost, 
low risk treatment, and high cervical cancer cost. Screening women with high 
CD4 is particularly cost-effective. VIA should be implemented among HIV-positive 
women in low-income settings.
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objeCtives: 10-20% of patients diagnosed with prostate cancer progress to meta-
static castration-resistant prostate cancer (mCRPC). Recently, four novel therapies 
have been introduced for the treatment of mCRPC; of these, abiraterone and sip-
uleucel-T have been studied in the asymptomatic, pre-docetaxel population. Both 
have shown clinical benefits compared to placebo. This study evaluated the cost-
effectiveness of abiraterone acetate and sipuleucel-T compared to prednisone in 
asymptomatic, pre-docetaxel mCRPC from a US societal perspective. Methods: 
A Markov model was constructed to simulate stable disease, progressed disease, 
and death. Survival and event rates were derived from published clinical trial data. 
Costs were derived from the literature and government reimbursement schedules. 
Utilities were derived from the literature. Outcomes were measured as average 
cost-effectiveness ratios (ACER), incremental cost-effectiveness ratios (ICER), and 
net monetary benefits (NMB). One-way and probabilistic sensitivity analyses were 
ing imatinib. Methods: A retrospective study spanning July 2004-December 2011 
analyzed data from 3 large integrated claims databases. Patients with a GIST-related 
ICD-9-CM code (151.0-154.0, 158.0, 159.0, 159.8, 159.9, 171.0, 171.4-171.9, 239.0) receiv-
ing imatinib were eligible if they (1) had a minimum eligibility of 6 months prior 
and 12 months following their first GIST diagnosis and (2) no previous diagnosis of 
cancer. Patients were divided into 2 cohorts: surgical (S) and non-surgical (NS). ST 
treatment patterns and corresponding GIST-related average monthly costs were evalu-
ated. Results: There were 57 (24 S, 33 NS), 98 (62 S, 36 NS), and 276 (156 S, 120 NS) 
patients in each of the 3 databases meeting all inclusion criteria, respectively. Average 
monthly cost of first-line therapy ranged from $26,465 to $78,081, with variation being 
driven by length of treatment. 42%-56% of NS and 41%-58% of S patients received 
second-line therapy, costing an average of $3,197-$5,334 per month. The majority of 
patients in each database received imatinib mono- or combination therapy as second-
line treatment (60%-74% NS; 74%-86% S). Third-line therapy was received by 13%-33% of 
NS and 19%-30% of S patients, with an average cost per month ranging from $2,354 to 
$30,993. Imatinib was also received third-line by the majority of the patients in 2 data-
bases (59%-67% NS, 60-75% S); sunitinib was most commonly utilized (43% NS, 58% S) in 
the third database. ConClusions: Over half of all patients receiving imatinib undergo 
surgery. Among both S and NS patients, second-line therapy for GIST was dominated 
by imatinib, while third-line therapy was dominated by imatinib or sunitinib.
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objeCtives: This study aimed to elucidate the hospitalization costs of adverse 
events (AEs) commonly associated with treatments for metastatic mela-
noma. Methods: Based on current drug labels and published clinical studies for 
the treatments of metastatic melanoma, 23 serious adverse events were identified. 
Length of stay (days) and hospitalization costs (2013 US $) for these 23 events (identi-
fied by primary discharge diagnoses) were examined using a large national claims 
database, in which patients with metastatic melanoma were identified from July 
2004 to November 2012. All analyses are presented descriptively. Results: There 
were 2998 patients with metastatic melanoma: most were male (59.5%) and the 
mean age was 55.8 years old. Hospitalizations due to acute myocardial infarction 
and sepsis incurred the longest median length of stay (9 and 6 days, respectively), 
followed by acidosis (5.5 days), acute kidney failure, pneumonitis, neuropathy, 
thrombocytopenia, and oliguria/anuria (all had 5 days). The highest inpatient cost 
per event was for acute myocardial infarction (mean $45,971 and median $53,747), 
followed by sepsis ($34,351 and $22,838), coma ($30,943 and $23,149), acute kidney 
failure ($30,485 and $19,972), neuropathy ($28,977 and $12,034), and pneumonitis 
($27,669 and $21,011). Colitis/diarrhea, cutaneous squamous cell carcinoma, throm-
bocytopenia, hyponatremia, oliguria/anuria, hypertension, anemia, and elevated 
liver enzymes were associated with mean costs per hospitalization ranging from 
$26,234 to $18,676. In contrast, the lower inpatient cost per event was for cellulitis 
(mean $16,828 and median $12,045), fever ($15,078 and $13,650), rash ($14,432 and 
$12,086), and nausea ($13,715 and $10,892). ConClusions: Hospital costs for the 
management of adverse events vary greatly. This study provides source data for 
economic evaluation of treatments for metastatic melanoma.
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objeCtives: A high percentage of patients recalled after screening mammography do 
not have cancer. The goal of this study is to describe the prevalence and cost to health 
plans of patient recall in the 6 months following screening mammography. Methods: 
The Truven Health MarketScan Commercial and Medicare Supplemental Databases were 
used to identify women aged 40-75 years undergoing screening mammography (index 
event) in 2010-2012. Women were required to have 12 months pre- and 6 months 
post-index continuous enrollment. Women with mammography or a breast cancer 
diagnosis in the 12 month pre-index period were excluded. Recall was defined as 
receipt of a second breast-related imaging procedure, coinciding with an abnormal 
mammogram diagnosis code or a breast-related diagnosis in the 6 months following 
the index screen. Payer cost per recall (2012 US$) was the sum of breast-related imagin-
ing procedures and associated visit costs in the 6 months post-index, excluding patient 
payments. Breast cancer treatment costs were not included in recall costs. Results: 
Of the 1,553,044 women who met the study inclusion criteria, 246,233 (15.9%) had 
an abnormal mammogram or related diagnosis code and had a subsequent imaging 
procedure in the 6 months post-index. The average cost per patient recalled was $1,082 
in the 6 months following screening mammography. The majority of recalls included 
diagnostic mammography (71.8%) or ultrasound (51.9%), which accounted for 12% and 
9% of recall costs, respectively. Office visits and pathology services accounted for 42% 
of recall costs. Biopsy was performed in 19.3% of recalled patients and accounted for 
27% of recall costs. MRI, fine needle aspiration, and ductogram accounted for < 5% of 
recall costs. ConClusions: Approximately one-in-six women undergoing screening 
mammography were recalled for further imaging within 6 months, with an average 
cost to health plans of $1,082 per patient. Improving breast cancer screening with a 
more accurate mammogram may significantly reduce payer costs.
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